NICE seeks more Abilify data

The U.K.'s NICE issued a preliminary appraisal for Abilify aripiprazole from Bristol-Myers Squibb Co. (NYSE:BMY) and Otsuka Pharmaceutical Co. Ltd. (Tokyo:4768) to treat schizophrenia in patients ages 15-17 years. In the appraisal, NICE asked the companies to provide more information on the clinical and cost effectiveness of Abilify in the age group compared with each of the antipsychotics routinely used in the U.K., including Zyprexa olanzapine from Eli Lilly and Co. (NYSE:LLY), Seroquel quetiapine from AstraZeneca plc (LSE:AZN; NYSE:AZN) and the generics risperidone, amisulpride and clozapine. ...